RecruitingPhase 2NCT05007873

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Studying Chronic graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Elias Jabbour
M.D. Anderson Cancer Center
Intervention
Dasatinib(drug)
Enrollment
70 enrolled
Eligibility
All sexes
Timeline
20212026

Study locations (1)

Collaborators

National Cancer Institute (NCI) · Astex Pharmaceuticals, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05007873 on ClinicalTrials.gov

Other trials for Chronic graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Chronic graft versus host disease

← Back to all trials